Samuel Goldhaber

Samuel Z. Goldhaber, MD is the section head for Vascular Medicine and director of the Thrombosis Research Group within the Cardiovascular Medicine Division of Brigham and Women’s Hospital (BWH). He is a professor of medicine at Harvard Medical School (HMS).

He received his medical degree from HMS. He completed his internal medicine residency at Peter Bent Brigham Hospital (now BWH) and was appointed as chief medical resident at the Veterans Administration Medical Center in West Roxbury (now VA Boston Healthcare System). He then completed his cardiology fellowship at Peter Bent Brigham Hospital (now BWH). Dr. Goldhaber is board certified in cardiovascular disease and internal medicine.

Dr. Goldhaber’s clinical interests include general cardiology as well as novel oral anticoagulants, stroke prevention in atrial fibrillation, reduction of inflammation to prevent myocardial infarction, and the epidemiology, management, and prevention of pulmonary embolism (PE) and deep vein thrombosis (DVT). He directs several Continuing Medical Education courses for BWH and HMS, including a 5-day update in cardiology for the practitioner and a 2-day course on Thrombosis and Thromboembolism. Dr. Goldhaber is committed to community outreach. He helped found the North American Thrombosis Forum (www.NATFonline.org), a nonprofit organization which educates healthcare practitioners and patients, and he serves as NATF’s president.

His extensive research and publications focus on PE, DVT, and stroke prevention in atrial fibrillation. He chairs the steering committee of the ATTRACT Trial, which is studying the optimal method to manage massive DVT. He is principal investigator of clinical and observational trials of PE and DVT prevention and treatment as well as of stroke prevention in atrial fibrillation. His research has received funding from the National Institutes of Health.

Education

Medical School

Harvard Medical School/ BWH, 1976

Residencies

• Peter Bent Brigham Hospital/Harvard Medical School, 1976 - 1979
• West Roxbury Veterans Administration Medical Center, 1979 - 1979

Board Certifications

• Internal Medicine, 1979
• Cardiovascular Disease, 1983

Fellowship

Peter Bent Brigham Hospital/Harvard Medical School, 1979 - 1982

Publications (Pulled from Harvard Catalyst Profiles):

1. Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, Jaff MR, Razavi MK, Kindzelski AL, Bashir R, Patel P, Sharafuddin M, Sichlau MJ, Saad WE, Assi Z, Hofmann LV, Kennedy M, Vedantham S. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. Circulation. 2019 Feb 26; 139(9):1162-1173.

2. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D, Harrell S, Hall R, Wyatt H, Piazza G. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Front Oncol. 2019; 9:45.

3. Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ. Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation. 2019 Feb 26; 139(9):1234-1236.

4. Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 Feb 18.

5. Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 2019 Feb 05; 139(6):787-798.

6. Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc. 2019 Feb 05; 8(3):e010510.

7. Chopard R, Piazza G, Hurwitz S, Fanikos J, Goldhaber SZ. Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. J Thromb Thrombolysis. 2019 Feb; 47(2):331-335.

8. Bikdeli B, Wang Y, Jimenez D, Ross JS, Monreal M, Goldhaber SZ, Krumholz HM. Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Intern Med. 2019 Feb 01; 179(2):263-265.

9. Kearon C, Gu CS, Julian JA, Goldhaber SZ, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Kahn SR, Kindzelski AL, Slater D, Geary R, Winokur R, Natarajan K, Dietzek A, Leung DA, Kim S, Vedantham S. Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. Thromb Haemost. 2019 Apr; 119(4):633-644.

10. Goldhaber SZ, Piazza G. Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. Eur Heart J. 2019 Jan 25.